Pierre L. Beaulieu

TL;DR: Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive reduction of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor, illustrating the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.

TL;DR: An enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein, or a salt or ester thereof, as an inhibitor of HCV NS5B polymerase.

TL;DR: In this article, a mixture of a 1,2-phenylenedi-amine and an aldehyde in wet DMF at room temperature is used to synthesize benzimidazoles.

TL;DR: A novel class of compounds and unique binding site expand the diversity of HCV antivirals currently under development and offer the potential to improve the treatment of chronic HCV infection.

TL;DR: BILD 1263 is reported on, which to the authors' knowledge is the first HSV RNR subunit-association inhibitor with antiviral activity in vivo and may lead to the design of new strategies to treat herpesvirus infections in humans.